Swiss Health Coverage Hurdles as Drugmakers Halt Submissions
Drugmakers are holding back health insurance applications in Switzerland due to fears that lower prices might undermine their…
Southeast Asia Oncology Drug Access Market Now Available; Profiles Roche, AstraZeneca, Merck, and Other Key Peers
Company Logo Key opportunities in the Southeast Asia oncology drug access market involve prioritizing accessibility, affordability, and availability…
Novartis in Albania | Novartis Albania
Novartis in Albania aims to discover and advance medical breakthroughs to improve the quality of life and longevity…
Novartis launches Pluvicto®, the Country’s First Regulatory Authority Approved Radioligand Therapy for Advanced Prostate Cancer
Novartis India announced the launch of Pluvicto(lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority-approved radioligand therapy for…
Novartis to build new radioligand therapy site in Texas to deliver next-generation treatments
Today Novartis announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will…
At the Bled Strategic Forum, Novartis calls for decisive action to improve European competitiveness
At the Bled Strategic Forum, Novartis participated in a panel titled “Healthcare Innovation as a Catalyst for European…